Regulatory Daily Summary
Regulatory Daily Summary: What Happened on November 15, 2026
FDA rejects Summit and Akeso’s ivonescimab for lung cancer
The agency said the drug did not extend patients’ lives, despite slowing disease progression.
Today in brief
The FDA turned down ivonescimab, developed by Summit Therapeutics and Akeso for a type of lung cancer, because it had not extended patients’ lives.1 Although the drug slowed cancer progression, FDA reviewers said the result did not support a favorable benefit-risk profile for approval.1
FDA says ivonescimab did not show a survival benefit
Summit said the FDA rejected ivonescimab, which Summit and Akeso developed for a type of lung cancer.1 The agency said in its letter to the companies that the treatment could not be approved because it had not extended patients’ lives.1
Ivonescimab slowed the worsening of patients’ cancer, but FDA reviewers concluded that the result did not establish a favorable balance of benefits and risks for approval.1
Also published
- FDA won't approve Summit, Akeso's ivonescimab pharmaphorum